CALLDORADO
8.9.2021 11:29:08 CEST | Business Wire | Press release
Calldorado has acquired longstanding partner Appvestor in a deal that will give its community of app developers instant access to advanced user acquisition tools.
The two companies make a good fit. Both are dedicated to helping app makers grow but in different ways. Calldorado’s unique technology helps Android developers keep existing user bases active and monetize them. Meanwhile, Appvestor’s AI-powered tools help them find new customers.
Appvestor was established in 2017 to build a technology engine that deploys machine learning and predictive algorithms to establish the best destinations for paid marketing campaigns. Its complete service to developers includes:
- A technology engine that maps campaign progress against revenue, conversion, and retention at a user level.
- Experience in running marketing campaigns that deliver large volumes of new users and the highest return on investment.
- Access to creative resources including studio and production.
- Expertise in ASO (App Store Optimization), which boosts the impact of campaigns and the number of customer conversions.
Calldorado has been working closely with Appvestor since its launch. Mathias Schroeder, co-CEO and co-founder of Calldorado, believes the buy-out is a logical move for both parties. He says: “Our tech does a brilliant job of keeping app users engaged. But it doesn’t find new ones. That’s why we have worked with many user acquisition platforms in the past.
"Appvestor was always the best. It’s the only one with predictive algorithms that can dynamically adjust a marketing campaign to maximize return on investment at all times. Paid user acquisition is a key strategic asset for us, so acquiring Appvestor makes perfect sense. We can’t wait to combine the two companies’ skills into a service that can really help scale our first-party and customer apps.”
The acquisition comes at a time of rapid growth in the app market. Total app downloads across both iOS and Google Play hit 130 billion (1 ). This was a 10% increase on 2019.
Meanwhile, total consumer spend on apps (in-app purchases, subscriptions, and premium apps) reached $143 billion in 2020 – up 20% in a year. App Annie believes the total could hit $270 billion by 2025.
The buoyant app market has fuelled a fast-growing app install ad sector. Developers increasingly rely on paid marketing to drive installs. So much so that analysts expect the total spend to rise from $57.8 billion in 2019 to $118 billion in 2022 (2).
About Calldorado
Calldorado’s unique user activation and monetization technology, the Caller SDK, helps Android app publishers keep their app user bases active, drives incremental traffic, and maximizes app revenue. Calldorado also publishes first-party apps; it launched its own content business with the acquisition of CIAmedia in 2018. A year later it acquired the call enrichment specialist adaffix. Calldorado was established in 2016 with headquarters in Denmark and is privately held.
1. Source: App Annie – State of Mobile 2021 https://www.appannie.com/en/go/state-of-mobile-2021/
2. Source: Appsflyer https://www.appsflyer.com/blog/trends-insights/app-install-ad-spend/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005536/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom